王琼
【摘要】 目的 觀察口服替莫唑胺联合同步放疗治疗恶性脑胶质瘤的临床效果。方法 26例恶性脑胶质瘤, 随机分为观察组和对照组, 每组13例。观察组给予替莫唑胺联合同步放疗治疗, 对照组给予单纯放疗, 观察比较两组患者的近期疗效、1年及2年生存率、生活质量改善情况。结果 治疗1~2个月后观察组总有效率为61.5%, 明显高于对照组的23.1%, 差异具有统计学意义(P<0.05)。治疗前观察组Karnofsky功能状态量表(KPS)评分为(68.7±8.6)分, 对照组KPS评分为(66.7±6.3)分, 比较差异无统计学意义(P>0.05)。治疗后观察组患者KPS评分为(86.2±10.0)分, 对照组KPS评分为(69.1±9.7)分;两组患者放疗结束后KPS评分较治疗前均升高, 且观察组明显高于对照组, 差异具有统计学意义(P<0.05)。观察组患者1年生存率为69.2%(9/13), 2年生存率为46.2%(6/13);对照组患者1年生存率为30.8%(4/13), 2年生存率为7.7%(1/13);两组1、2年生存率比较, 差异具有统计学意义(P<0.05)。结论 口服替莫唑胺联合同步放疗治疗恶性脑胶质瘤疗效显著, 可显著提高患者生存率, 改善患者生活质量, 值得推广应用。
【关键词】 替莫唑胺;放疗;恶性脑胶质瘤
DOI:10.14163/j.cnki.11-5547/r.2016.35.043
【Abstract】 Objective To observe clinical effect by oral administration of temozolomide combined with concurrent radiotherapy in the treatment of malignant brain glioma. Methods A total of 26 patients with malignant brain glioma were randomly divided into observation group and control group, with 13 cases in each group. The observation group received temozolomide combined with concurrent radiotherapy for treatment, and the control group received single radiotherapy instead. Observation and comparison were made on short-term curative effect, 1-year and 2-year survival rates, and improvements of quality of life between the two groups. Results After 1~2 months of treatment, the observation group had obviously higher total effective rate as 61.5% than 23.1% in the control group, and their difference had statistical significance (P<0.05). Before treatment, the observation group had Karnofsky performance status (KPS) score as (68.7±8.6) points, which was (66.7±6.3) points in the control group, and their difference had no statistical significance (P>0.05). After treatment, the observation group had KPS score as (86.2±10.0) points, and the control group had KPS score as (69.1±9.7) points. Both groups had higher KPS scores after treatment than those before treatment, and the observation group had much higher score than the control group. Their difference had statistical significance (P<0.05). The observation group had 1-year survival rate as 69.2% (9/13) and 2-year survival rate as 46.2% (6/13). The control group had 1-year survival rate as 30.8% (4/13) and 2-year survival rate as 7.7% (1/13). The difference of 1-year and 2-year survival rates had statistical significance between the two groups (P<0.05). Conclusion Oral administration of temozolomide combined with concurrent radiotherapy shows excellent curative effect in the treatment of malignant brain glioma. This method can remarkably improve survival rate and quality of life in patients, and it is worth promoting and applying.
【Key words】 Temozolomide; Radiotherapy; Malignant brain glioma
恶性脑胶质瘤是一种常见的原发性脑肿瘤, 分为间变性星形细胞瘤和胶质母细胞瘤, 其恶性程度高, 患者生存时间短, 平均生存时间在8~12个月左右[1-3], 传统手术治疗难以彻底清除肿瘤组织, 且因为血脑屏障和恶性脑胶质瘤细胞对多数化疗药物有耐受性, 传统烷化剂类化疗药物治疗该疾病并不能取得良好的效果, 且副作用大[4-6]。目前临床上多采用手术、化疗配合放疗的综合方法治疗恶性脑胶质瘤, 可显著延长患者的生存时间[7, 8]。本文将以本院收治的恶性脑胶质瘤患者为研究对象, 观察口服替莫唑胺联合同步放疗治疗该疾病的临床效果, 现报告如下。
1 资料与方法
1. 1 一般资料 选取2012年9月~2014年9月期间本院收治的26例恶性脑胶质瘤, 将其随机分为观察组和对照组, 每组13例。观察组中男8例, 女5例;年龄26~76岁, 平均年龄(46.8±10.5)岁;病理分级Ⅲ级5例, Ⅳ级8例。……